[go: up one dir, main page]

FI20105572A0 - Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt - Google Patents

Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt

Info

Publication number
FI20105572A0
FI20105572A0 FI20105572A FI20105572A FI20105572A0 FI 20105572 A0 FI20105572 A0 FI 20105572A0 FI 20105572 A FI20105572 A FI 20105572A FI 20105572 A FI20105572 A FI 20105572A FI 20105572 A0 FI20105572 A0 FI 20105572A0
Authority
FI
Finland
Prior art keywords
lactamase
methods
modified beta
uses related
beta
Prior art date
Application number
FI20105572A
Other languages
English (en)
Swedish (sv)
Inventor
Pertti Koski
Ulla Airaksinen
Katja Vaelimaeki
Original Assignee
Prevab R Lcc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prevab R Lcc filed Critical Prevab R Lcc
Priority to FI20105572A priority Critical patent/FI20105572A0/fi
Publication of FI20105572A0 publication Critical patent/FI20105572A0/fi
Priority to DK11786185.6T priority patent/DK2576776T3/en
Priority to PL11786185T priority patent/PL2576776T3/pl
Priority to KR1020127033615A priority patent/KR101708703B1/ko
Priority to BR112012030029-6A priority patent/BR112012030029B1/pt
Priority to JP2013511709A priority patent/JP5827681B2/ja
Priority to RU2012155420/10A priority patent/RU2570551C2/ru
Priority to PCT/FI2011/050450 priority patent/WO2011148041A1/en
Priority to CN201180035810.5A priority patent/CN103038341B/zh
Priority to HUE11786185A priority patent/HUE030689T2/en
Priority to ES11786185.6T priority patent/ES2588279T3/es
Priority to EP11786185.6A priority patent/EP2576776B1/en
Priority to HK13111298.1A priority patent/HK1183905B/en
Priority to US13/699,434 priority patent/US9034602B2/en
Priority to CA2800671A priority patent/CA2800671C/en
Priority to AU2011257092A priority patent/AU2011257092C1/en
Priority to ZA2012/08948A priority patent/ZA201208948B/en
Priority to US14/047,882 priority patent/US8894994B2/en
Priority to US14/517,539 priority patent/US9301995B2/en
Priority to US14/676,559 priority patent/US9301996B2/en
Priority to US15/054,292 priority patent/US9587234B2/en
Priority to US15/138,767 priority patent/US9765320B2/en
Priority to US15/417,501 priority patent/US10041056B2/en
Priority to US15/661,416 priority patent/US10253306B2/en
Priority to US16/279,547 priority patent/US11214787B2/en
Priority to US17/533,739 priority patent/US20220090044A1/en
Priority to US18/315,122 priority patent/US20230332128A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/86—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in cyclic amides, e.g. penicillinase (3.5.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/52—Genes encoding for enzymes or proenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/75—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Bacillus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/02—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amides (3.5.2)
    • C12Y305/02006—Beta-lactamase (3.5.2.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
FI20105572A 2010-05-24 2010-05-24 Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt FI20105572A0 (fi)

Priority Applications (27)

Application Number Priority Date Filing Date Title
FI20105572A FI20105572A0 (fi) 2010-05-24 2010-05-24 Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
AU2011257092A AU2011257092C1 (en) 2010-05-24 2011-05-17 Modified beta-lactamases and methods and uses related thereto
HK13111298.1A HK1183905B (en) 2010-05-24 2011-05-17 Modified beta-lactamases and methods and uses related thereto
CA2800671A CA2800671C (en) 2010-05-24 2011-05-17 Modified beta-lactamases and methods and uses related thereto
KR1020127033615A KR101708703B1 (ko) 2010-05-24 2011-05-17 변형된 베타-락타마아제 및 이와 관련된 방법 및 용도
BR112012030029-6A BR112012030029B1 (pt) 2010-05-24 2011-05-17 Beta-lactamases modificadas, métodos, polinucleotídeo e composições relacionadas
JP2013511709A JP5827681B2 (ja) 2010-05-24 2011-05-17 改変型β−ラクタマーゼ並びにそれに関する方法及び使用
RU2012155420/10A RU2570551C2 (ru) 2010-05-24 2011-05-17 Бета-лактамаза, способ ее модификации, получения и применение
PCT/FI2011/050450 WO2011148041A1 (en) 2010-05-24 2011-05-17 Modified beta-lactamases and methods and uses related thereto
CN201180035810.5A CN103038341B (zh) 2010-05-24 2011-05-17 经修饰的β-内酰胺酶及其相关方法和应用
HUE11786185A HUE030689T2 (en) 2010-05-24 2011-05-17 Modified beta-lactamases and related methods and applications
ES11786185.6T ES2588279T3 (es) 2010-05-24 2011-05-17 Beta-lactamasas modificadas y métodos y usos relacionados con las mismas
EP11786185.6A EP2576776B1 (en) 2010-05-24 2011-05-17 Modified beta-lactamases and methods and uses related thereto
DK11786185.6T DK2576776T3 (en) 2010-05-24 2011-05-17 MODIFIED betalactamases AND PRACTICES AND USES RELATED ARTICLES
US13/699,434 US9034602B2 (en) 2010-05-24 2011-05-17 Modified beta-lactamases and methods and uses related thereto
PL11786185T PL2576776T3 (pl) 2010-05-24 2011-05-17 Modyfikowane beta-laktamazy oraz powiązane z nimi sposoby i zastosowania
ZA2012/08948A ZA201208948B (en) 2010-05-24 2012-11-27 Modified beta-lactamases and methods and uses related thereto
US14/047,882 US8894994B2 (en) 2010-05-24 2013-10-07 Modified beta-lactamases and methods and uses related thereto
US14/517,539 US9301995B2 (en) 2010-05-24 2014-10-17 Modified beta-lactamases and methods and uses related thereto
US14/676,559 US9301996B2 (en) 2010-05-24 2015-04-01 Modified beta-lactamases and methods and uses related thereto
US15/054,292 US9587234B2 (en) 2010-05-24 2016-02-26 Modified beta-lactamases and methods and uses related thereto
US15/138,767 US9765320B2 (en) 2010-05-24 2016-04-26 Modified beta-lactamases and methods and uses related thereto
US15/417,501 US10041056B2 (en) 2010-05-24 2017-01-27 Modified beta-lactamases and methods and uses related thereto
US15/661,416 US10253306B2 (en) 2010-05-24 2017-07-27 Modified beta-lactamases and methods and uses related thereto
US16/279,547 US11214787B2 (en) 2010-05-24 2019-02-19 Modified beta-lactamases and methods and uses related thereto
US17/533,739 US20220090044A1 (en) 2010-05-24 2021-11-23 Modified beta-lactamases and methods and uses related thereto
US18/315,122 US20230332128A1 (en) 2010-05-24 2023-05-10 Modified beta-lactamases and methods and uses related thereto

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FI20105572A FI20105572A0 (fi) 2010-05-24 2010-05-24 Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt

Publications (1)

Publication Number Publication Date
FI20105572A0 true FI20105572A0 (fi) 2010-05-24

Family

ID=42234353

Family Applications (1)

Application Number Title Priority Date Filing Date
FI20105572A FI20105572A0 (fi) 2010-05-24 2010-05-24 Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt

Country Status (16)

Country Link
US (11) US9034602B2 (fi)
EP (1) EP2576776B1 (fi)
JP (1) JP5827681B2 (fi)
KR (1) KR101708703B1 (fi)
CN (1) CN103038341B (fi)
AU (1) AU2011257092C1 (fi)
BR (1) BR112012030029B1 (fi)
CA (1) CA2800671C (fi)
DK (1) DK2576776T3 (fi)
ES (1) ES2588279T3 (fi)
FI (1) FI20105572A0 (fi)
HU (1) HUE030689T2 (fi)
PL (1) PL2576776T3 (fi)
RU (1) RU2570551C2 (fi)
WO (1) WO2011148041A1 (fi)
ZA (1) ZA201208948B (fi)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8992422B2 (en) 2006-03-23 2015-03-31 Ethicon Endo-Surgery, Inc. Robotically-controlled endoscopic accessory channel
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
CA2942971C (en) * 2014-04-17 2023-03-14 Synthetic Biologics, Inc. Beta-lactamases with improved properties for therapy
US11034966B2 (en) 2014-08-28 2021-06-15 Synthetic Biologics, Inc. E. coli-based production of beta-lactamase
JP6672277B2 (ja) 2014-10-08 2020-04-01 シンセティック・バイオロジクス・インコーポレイテッド ベータラクタマーゼ製剤およびその使用
FR3027307B1 (fr) * 2014-10-16 2016-11-04 Azurrx Sas Molecule proteique hybride apte a inhiber au moins un antibiotique et composition pharmaceutique la comportant
US9744221B2 (en) 2014-12-23 2017-08-29 Synthetic Biologics, Inc. Method and compositions for inhibiting or preventing adverse effects of oral antibiotics
JP6810697B2 (ja) 2015-02-23 2021-01-13 シンセティック・バイオロジクス・インコーポレイテッド 腸内マイクロバイオームの保護のために抗生物質と共に使用するカルバペネマーゼ
US10709773B2 (en) 2015-03-06 2020-07-14 Synthetic Biologics, Inc. Safe and effective beta-lactamase dosing for microbiome protection
JP6845258B6 (ja) * 2016-02-23 2021-04-28 ダ・ボルテラ ベータ−ラクタマーゼ変異体
US11185555B2 (en) 2016-04-11 2021-11-30 Noah James Harrison Method to kill pathogenic microbes in a patient
JP7516007B2 (ja) * 2016-06-28 2024-07-16 セリバ・バイオロジクス・インコーポレイテッド 経口抗生物質からのマイクロバイオーム防御
CA3042525A1 (en) * 2016-11-01 2018-05-11 Synthetic Biologics, Inc. Methods and compositions for attenuating antibiotic resistance
CN110157699B (zh) * 2018-02-12 2021-07-23 中国科学院微生物研究所 β-内酰胺酶及其编码基因以及它们的应用
EP3829637A1 (en) 2018-08-05 2021-06-09 Da Volterra Method for improving anticancer agent efficacy
CN112689506A (zh) 2018-08-05 2021-04-20 达·沃尔泰拉公司 用于治疗移植物抗宿主疾病的组合物
CN110777178A (zh) * 2019-12-02 2020-02-11 河北慧林生物科技有限公司 固定化羧基酯水解酶在氯唑西林、双氯西林、氟氯西林及苯唑西林侧链合成中的应用
CN114075560A (zh) * 2020-08-18 2022-02-22 杭州俊丰生物工程有限公司 一种β-内酰胺酶的稳定组合物
EP4148136A1 (en) 2021-09-08 2023-03-15 Da Volterra An engineered yeast cell for the delivery of antibiotic-inactivating enzymes

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL197650A (fi) 1954-05-29
US2941995A (en) 1957-08-02 1960-06-21 Beecham Res Lab Recovery of solid 6-aminopenicillanic acid
US2982696A (en) 1959-05-01 1961-05-02 Schenley Ind Inc Ion-exchange procedures for the purification of penicillinase
US3070511A (en) 1960-02-10 1962-12-25 Lepetit Spa Process for preparing 6-aminopenicillanic acid
US3150059A (en) 1962-12-26 1964-09-22 Lilly Co Eli Penicillin deacylation via actinoplanaceae fermentation
US3239394A (en) 1964-06-15 1966-03-08 Merck & Co Inc Process for producing 7-amino-cephalosporanic acid
US3499909A (en) 1966-05-18 1970-03-10 Koninklijke Gist Spiritus Process for production of 6-aminopenicillanic acid
US3488729A (en) 1966-08-22 1970-01-06 Lilly Co Eli Cephalothin ester
GB1241844A (en) 1968-08-23 1971-08-04 Beecham Group Ltd Penicillins
GB1463513A (en) 1974-08-13 1977-02-02 Beecham Group Ltd Enzymes
FI59265C (fi) 1974-08-13 1981-07-10 Beecham Group Ltd Foerfarande foer framstaellning av 6-aminopenicillansyra
GB2199582A (en) 1987-01-07 1988-07-13 Bayer Ag Analogues of pancreatic secretory trypsin inhibitor
FR2613624B1 (fr) 1987-04-10 1990-11-23 Roussy Inst Gustave Composition pharmaceutique, administrable par voie orale, destinee a reduire les effets des b-lactamines
CA2007083A1 (en) 1989-01-09 1990-07-09 Nobuhiko Katunuma Pharmaceutical use of trypstatin
CS275231B2 (en) 1989-09-29 1992-02-19 Ustav Makormolekularni Chemie Medicine bottle
FI920206A0 (fi) 1992-01-17 1992-01-17 Pekka Untamo Heino Medicinsk anvaendning, medicinskt foerfarande och preparat.
CN1190434A (zh) 1995-07-07 1998-08-12 诺沃挪第克公司 用不能形成芽孢的芽孢杆菌生产蛋白质的方法
US7585674B2 (en) 2001-05-29 2009-09-08 Kao Corporation Host microorganisms
FI112666B (fi) 2001-11-06 2003-12-31 Ipsat Therapies Oy Itiöimätön Bacillus subtilis, sen valmistus ja käyttö
FR2843302B1 (fr) 2002-08-09 2004-10-22 Centre Nat Rech Scient Forme galenique pour la delivrance colique de principes actifs
US7323303B2 (en) * 2003-03-31 2008-01-29 Hong Kong Polytechnic University Modified β-lactamases and uses thereof
EP1564286A1 (en) 2004-02-11 2005-08-17 Université de Liège Hybrid proteins of beta-lactamase class A
IL163821A0 (en) * 2004-08-31 2005-12-18 Ravgalai Ltd Rapax Consortium Software for management of legal motions Methods and kits for the detection of biotoxic andantibiotic residues
US8106000B2 (en) 2005-05-18 2012-01-31 Da Volterra Colonic delivery of adsorbents
FI119190B (fi) 2006-06-21 2008-08-29 Ipsat Therapies Oy Modifioitu beta-laktamaasi ja menetelmä sen valmistamiseksi
FI119678B (fi) * 2006-11-28 2009-02-13 Ipsat Therapies Oy Beta-laktamaasin käyttö
FI20105572A0 (fi) 2010-05-24 2010-05-24 Prevab R Lcc Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt

Also Published As

Publication number Publication date
RU2570551C2 (ru) 2015-12-10
US20160168557A1 (en) 2016-06-16
BR112012030029A2 (pt) 2017-05-02
US20190169590A1 (en) 2019-06-06
US20230332128A1 (en) 2023-10-19
US20140127785A1 (en) 2014-05-08
US9587234B2 (en) 2017-03-07
CA2800671A1 (en) 2011-12-01
US9301995B2 (en) 2016-04-05
US10253306B2 (en) 2019-04-09
US20130216622A1 (en) 2013-08-22
RU2012155420A (ru) 2014-06-27
US20160230160A1 (en) 2016-08-11
US11214787B2 (en) 2022-01-04
US8894994B2 (en) 2014-11-25
DK2576776T3 (en) 2016-10-03
WO2011148041A1 (en) 2011-12-01
AU2011257092A1 (en) 2013-01-10
EP2576776A4 (en) 2014-01-22
EP2576776A1 (en) 2013-04-10
US20170145402A1 (en) 2017-05-25
AU2011257092B2 (en) 2013-12-19
ZA201208948B (en) 2014-02-26
US20150209418A1 (en) 2015-07-30
PL2576776T3 (pl) 2017-01-31
US10041056B2 (en) 2018-08-07
US20170327812A1 (en) 2017-11-16
US9301996B2 (en) 2016-04-05
KR101708703B1 (ko) 2017-02-21
US20150056178A1 (en) 2015-02-26
CA2800671C (en) 2018-09-18
JP2013529905A (ja) 2013-07-25
US20220090044A1 (en) 2022-03-24
US9034602B2 (en) 2015-05-19
BR112012030029B1 (pt) 2021-08-17
KR20130133648A (ko) 2013-12-09
ES2588279T3 (es) 2016-10-31
CN103038341B (zh) 2016-04-20
HK1183905A1 (zh) 2014-01-10
AU2011257092C1 (en) 2014-06-19
EP2576776B1 (en) 2016-07-13
US9765320B2 (en) 2017-09-19
CN103038341A (zh) 2013-04-10
JP5827681B2 (ja) 2015-12-02
HUE030689T2 (en) 2017-05-29

Similar Documents

Publication Publication Date Title
IL288070B (en) Oplophorus-derived luciferases, novel coelenterazine substrates, and methods of use
CY2021021I2 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
FI20105572A0 (fi) Muokattu beeta-laktamaasi ja siihen liittyvät menetelmät ja käytöt
BR112012017441A2 (pt) compostos e métodos
FI20105901A0 (fi) Laite ja menetelmä
FI20100223A0 (fi) Menetelmä ja hissijärjestely
BR112013001592A2 (pt) artigo e método
BR112014012137A2 (pt) anticorpos anti-fgfr2 e suas utilizações
HRP20150316T1 (xx) Heterofazni propilen kopolimer sa odliäśnim balansom udara/ krutosti
HRP20181457T1 (hr) Anti-htra1 protutijela i postupci uporabe
BR112013010847A2 (pt) artigo e método
BR112012027159A2 (pt) estrutura e método
FI20100304A0 (fi) Patjan rakenne ja patjajärjestelmä
LT2605789T (lt) Modifikuoti relaksino polipeptidai ir jų panaudojimas
CO6990717A2 (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
DK2613884T3 (da) Findelingsindretning
HRP20171579T8 (hr) Antigljivična sredstva i njihova upotreba
HRP20160922T1 (hr) Oligopeptidni spojevi i njihove uporabe
BR112013016641A2 (pt) artigo e método
EP2613438A4 (en) AMPLIFIER
CO6781486A2 (es) Compuestos y su uso
DE112011102851A5 (de) Drehsteller
DE11786796T8 (de) Antigenpeptid und verwendung davon
BR112012021749A2 (pt) processos e compostos
DK2571902T3 (da) Ny fremgangsmåde

Legal Events

Date Code Title Description
FD Application lapsed